Biosimilars or Biologics : What’s the difference? University of British Columbia. Therapeutics Initiative
Therapeutics Letter 123 examines biologics and biosimilars. Conclusions: Biosimilars are not identical to biologics but lie within the variability range of the originator biologic. Government regulators around the world approve biosimilars based on evidence that biosimilars are not inferior to the originator biologic product in terms of safety and effectiveness. Systematic reviews of switching from biologics to biosimilars found no meaningful differences in safety and effectiveness between them. Biosimilars are less expensive than originator biologics.
Item Citations and Data
Attribution-NonCommercial-NoDerivatives 4.0 International